Health
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
PRINCETON, N.J., December 11, 2025--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/7df2d92dd0eefd370d0baf701e3c9671"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JyH4z1bZTYVWG2lADKcpdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7df2d92dd0eefd370d0baf701e3c9671","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/utgn.XoIs7giIEboqyRRNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7df2d92dd0eefd370d0baf701e3c9671","width":1200,"height":165}},"lazy":false},{"type":"text","content":"The U.S. FDA assigned a target action date of April 8, 2026","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., December 11, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric (12 years and older) patients with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL). The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 8, 2026.","length":555,"tagName":"p"},{"type":"text","content":""The FDA’s acceptance of our supplemental Biologics License Application for priority review marks a pivotal milestone as we aim to bring a new and much-needed first-line option to adolescents and adults newly diagnosed with advanced-stage classical Hodgkin lymphoma," said Monica Shaw, Senior Vice President, Oncology Commercialization, Bristol Myers Squibb. "Opdivo in combination with AVD represents a potential new standard of care in the frontline treatment of advanced cHL for adolescents and adults. Hodgkin lymphoma remains a challenging disease, with an ongoing need for therapies that may deliver meaningful and durable outcomes early in a patient’s treatment journey. We look forward to collaborating with the FDA throughout the review process to bring this important option to patients as quickly as possible."","length":841,"tagName":"p"},{"type":"text","c...